Synairgen Research Ltd

Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www. synairgen.com.
Social Link - Twitter: https://twitter.com/synairgenplc
Social Link - Linkedin: http://www. linkedin.com/company /synairgen-research-ltd
Employee Count: 23
Keywords: biotechnology research